More Rigorous Assessments Ahead Under Australia’s Program For Subsidizing Rare Disease Drugs
Executive Summary
Medicines accepted in Australia’s Life Savings Drugs Program for subsidizing access to very expensive drugs for serious rare diseases are to be subject to a review of usage and financial costs after 24 months, according to one of a number of reforms the government is introducing.